Fortress Biotech, Inc.
FBIOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Fortress Biotech, Inc. focuses on Biotechnology services and products. Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company carries a $90.7M market cap, placing it firmly in the micro-cap category. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squam.
Market Cap
$90.7M
Beta
1.19
P/E (TTM)
0.98
P/E (Fwd)
-1.55
EPS (TTM)
$2.77
EPS (Fwd)
$-1.76
ROE
116.0%
ROA
-7.8%
Cash
$196.6M
Total Debt
$53.3M
Free CF
-$17.1M
52W Change
-24.2%
Annual Financials
Cash vs Debt
Where FBIO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, FBIO finished 6.19% below its 150-day moving average ($2.91) and 9.30% below its 200-day moving average ($3.01). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FBIO overbought or oversold?
At the September 3, 2026 close, FBIO's RSI(14) was 35.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $196.6M in cash comfortably exceeding the $53.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$17.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 116.0% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $75.7M to $63.3M.
With cash comfortably exceeding debt, FBIO has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing FBIO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.